Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma

Cancer Letters

Volumn 263, Issue 1, 2008, Pages 44-52

  Wang, Yu Long ^a   Wang, Jiu Cun ^b   Wu, Yi ^a   Zhang, Ling ^a   Huang, Cai Ping ^a   Shen, Qiang ^a   Zhu, Yong Xue ^a   Li, Duan Shu ^a   Ji, Qing Hai ^a  

^a FUDAN UNIVERSITY   (China)

^b Institute of Genetics   (China)

Author keywords

BRAF mutation; Papillary thyroid carcinoma; PTEN; RET rearrangement; Target therapy

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CHINESE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; H4 PTEN GENE; HUMAN; MALE; ONCOGENE; ONCOGENE RET; PREDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION; PTC GENE; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; CYTOSKELETAL PROTEINS; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; PTEN PHOSPHOHYDROLASE; THYROID NEOPLASMS;

EID: 41149163128     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.12.018     Document Type: Article

References (46)

1. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 (2006) 2164-2167
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
3. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63 (2003) 1454-1457
4. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115 (2005) 1068-1081
5. Mitsutake N., Miyagishi M., Mitsutake S., Akeno N., Mesa Jr. C., Knauf J.A., et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147 (2006) 1014-1019
6. Puxeddu E., Zhao G., Stringer J.R., Medvedovic M., Moretti S., and Fagin J.A. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutat. Res. 570 (2005) 17-32
7. Carta C., Moretti S., Passeri L., Barbi F., Avenia N., Cavaliere A., et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin. Endocrinol. (Oxf.) 64 (2006) 105-109
8. Fagin J.A. Genetics of papillary thyroid cancer initiation: implications for therapy. Trans. Am. Clin. Climatol. Assoc. 116 (2005) 259-269 discussion 269-271
9. Kim T.Y., Kim W.B., Rhee Y.S., Song J.Y., Kim J.M., Gong G., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 65 (2006) 364-368
10. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 (2004) 2954-2963
11. Frame S., and Balmain A. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr. Opin. Genet. Dev. 10 (2000) 106-113
12. Zbuk K.M., and Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat. Rev. Cancer. 7 (2007) 35-45
13. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96 (1999) 1563-1568
14. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25 (2007) 884-896
15. Salvatore G., De Falco V., Salerno P., Nappi T.C., Pepe S., Troncone G., et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer. Res. 12 (2006) 1623-1629
16. Milano A., Chiofalo M.G., Basile M., Salzano De Luna A., Pezzullo L., and Caponigro F. New molecular targeted therapies in thyroid cancer. Anticancer Drugs 17 (2006) 869-879
17. Liu R.T., Chen Y.J., Chou F.F., Li C.L., Wu W.L., Tsai P.C., et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin. Endocrinol. (Oxf.) 63 (2005) 461-466
18. Lam K.Y., Lo C.Y., and Leung P.S. High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas. Eur. J. Endocrinol. 147 (2002) 741-745
19. Hedinger C., Williams E.D., and Sobin L.H. Histological Typing of Thyroid Tumours (1988), Springer-Verlag, Berlin
20. Xing M., Cohen Y., Mambo E., Tallini G., Udelsman R., Ladenson P.W., et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 64 (2004) 1664-1668
21. Sapio M.R., Posca D., Raggioli A., Guerra A., Marotta V., Deandrea M., et al. TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin. Endocrinol. (Oxf.) 66 (2007) 678-683
22. Zhu X.L., Zhou X.Y., Zhang T.M., and Zhu X.Z. Expressions of wild type-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation. Zhonghua Bing Li Xue Za Zhi 35 (2006) 87-91
23. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90 (2005) 6373-6379
24. Wang Y.L., Zhang R.M., Luo Z.W., Wu Y., Du X., Wang Z.Y., et al. High frequency of level II-V lymph node involvement in RET/PTC positive papillary thyroid carcinoma. Eur. J. Surg. Oncol. 34 (2008) 77-81
25. Smyth P., Finn S., Cahill S., O'regan E., Flavin R., O'leary J.J., et al. ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int. J. Surg. Pathol. 13 (2005) 1-8
26. Kim T.Y., Kim W.B., Song J.Y., Rhee Y.S., Gong G., Cho Y.M., et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin. Endocrinol. (Oxf.) 63 (2005) 588-593
27. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. AJCC Cancer Staging Manual. sixth ed. (2002), Springer-Verlag, NY
28. Salvatore G., Giannini R., Faviana P., Caleo A., Migliaccio I., Fagin J.A., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 89 (2004) 5175-5180
29. Chung K.W., Yang S.K., Lee G.K., Kim E.Y., Kwon S., Lee S.H., et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin. Endocrinol. (Oxf.) 65 (2006) 660-666
30. Ciampi R., and Nikiforov Y.E. Ret/Ptc Rearrangements and Braf Mutations in Thyroid Tumorigenesis. Endocrinology 148 (2007) 936-941
31. Ouyang B., Knauf J.A., Smith E.P., Zhang L., Ramsey T., Yusuff N., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12 (2006) 1785-1793
32. Zhu Z., Ciampi R., Nikiforova M.N., Gandhi M., and Nikiforov Y.E. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91 (2006) 3603-3610
33. Xu X., Quiros R.M., Gattuso P., Ain K.B., and Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63 (2003) 4561-4567
34. Vasko V., Hu S., Wu G., Xing J.C., Larin A., Savchenko V., et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J. Clin. Endocrinol. Metab. 90 (2005) 5265-5269
35. Sugg S.L., Ezzat S., Rosen I.B., Freeman J.L., and Asa S.L. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 83 (1998) 4116-4122
36. Oler G., Ebina K.N., Michaluart Jr. P., Kimura E.T., and Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin. Endocrinol. (Oxf.) 62 (2005) 509-511
37. Abrosimov A., Saenko V., Rogounovitch T., Namba H., Lushnikov E., Mitsutake N., et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int. J. Cancer. 120 (2007) 196-200
38. Nikiforova M.N., Ciampi R., Salvatore G., Santoro M., Gandhi M., Knauf J.A., et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 209 (2004) 1-6
39. Adeniran A.J., Zhu Z., Gandhi M., Steward D.L., Fidler J.P., Giordano T.J., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30 (2006) 216-222
40. Unger K., Zitzelsberger H., Salvatore G., Santoro M., Bogdanova T., Braselmann H., et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89 (2004) 4272-4279
41. Nikiforova M.N., Stringer J.R., Blough R., Medvedovic M., Fagin J.A., and Nikiforov Y.E. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290 (2000) 138-141
42. Gandhi M., Medvedovic M., Stringer J.R., and Nikiforov Y.E. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 25 (2006) 2360-2366
43. Roccato E., Bressan P., Sabatella G., Rumio C., Vizzotto L., Pierotti M.A., et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 65 (2005) 2572-2576
44. Schwaller J., Anastasiadou E., Cain D., Kutok J., Wojiski S., Williams I.R., et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 97 (2001) 3910-3918
45. Celetti A., Cerrato A., Merolla F., Vitagliano D., Vecchio G., and Grieco M. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 23 (2004) 109-121
46. Fugazzola L., Mannavola D., Cirello V., Vannucchi G., Muzza M., Vicentini L., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin. Endocrinol. (Oxf.) 61 (2004) 239-243